HR-positive HER2-negative breast cancer

October 16, 2019

Kisqali-Faslodex Combo Prolongs Survival of Postmenopausal Women with Advanced Breast Cancer, Phase 3 Trial Shows

News

Kisqali (ribociclib) in combination with Faslodex (fulvestrant) prolongs the survival of postmenopausal women with HR-positive, HER2-negative, advanced or metastatic breast cancer, interim analysis of a Phase 3 clinical trial shows. ... Read more

August 16, 2019

Trial Testing Eftilagimod Alpha-Chemo Combo for HR-positive Advanced Breast Cancers Now Fully Enrolled

News

Immunotep has completed patient enrollment for its Phase 2b trial evaluating eftilagimod alpha (IMP321) — an investigational therapy that stimulates the immune system to fight cancer — in combination with ... Read more

August 2, 2019

Verzenio-Faslodex Combo Prolongs Survival in Advanced Breast Cancer, Interim Phase 3 Data Show

News

Verzenio (abemaciclib) in combination with Faslodex (fulvestrant) prolongs the survival of women with HR-positive, HER2-negative advanced or metastatic breast cancer who had been previously treated with endocrine therapy, interim analysis ... Read more

June 20, 2018

Most Women with Early Breast Cancer Can Forgo Chemotherapy, Large Trial Finds

News

Seventy percent of women with the most common form of early breast cancer can avoid chemotherapy after surgery, according to a landmark Phase 3 clinical trial. The trial’s results, “Adjuvant ... Read more

November 15, 2017November 15, 2017

European Commission Approves Faslodex-Ibrance Combo for Advanced Breast Cancer

News

The European Commission (EC) has extended the approval of AstraZeneca‘s breast cancer therapy Faslodex (fulvestrant) to be used in combination with Ibrance (palbociclib) for advanced breast cancers. The combination can now be used ... Read more

May 11, 2017May 11, 2017

FDA Approves Kisqali Femara Co-Pack to Treat Subset of Advanced Breast Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has approved Novartis Oncology‘s Kisqali Femara Co-Pack for to treat postmenopausal women with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer. The Co-Pack, which includes Kisqali ... Read more